The impact of host genetics on HIV infection and disease progression in the era of highly active antiretroviral therapy : AIDS

Secondary Logo

Journal Logo

Review Papers: Epidemiology, social, cultural, and political

The impact of host genetics on HIV infection and disease progression in the era of highly active antiretroviral therapy

Tang, Jianminga; Kaslow, Richard Aa,b

Author Information
  • Free


Suspicion that host genetic factors determine variability in the course of natural HIV-1 infection deepened throughout the 1980s and early 1990s [1,2], but only relatively recently have we recognized the impact of human genetic variation on HIV/AIDS as a complex phenomenon [3–11]. As the control and prevention of HIV-1 infection with highly active antiretroviral therapy (HAART) became more widely available, the growing opportunity for pharmacogenetic studies [12–14] was also accompanied by uncertainty about the residual host genetic influences on HIV/AIDS.

The critical assessment of existing immunogenetic and pharmacogenetic findings in HIV/AIDS is not an easy task because other factors such as age [15–18], sex [19–21], ethnicity [22], and viral characteristics [23–28] can also play important roles. Evaluation is further complicated by the variety of terminology (Table 1) and laboratory techniques used by individual investigators. Nevertheless, consensus data from some of the more widely recognized and well-designed studies have provided useful benchmarks in further experimental and translational research; moreover, both the concepts of genetics and the functional consequences of human polymorphisms reflected in studies of HIV/AIDS are being explored in other disease systems [29–34]. These rapidly expanding enterprises should eventually promote a more comprehensive view of the evolving host–pathogen relationships and their relevance to public health.

Table 1:
Glossary: genetic and related terminologya as used in the text.

The impact of host genetics on HIV/AIDS before highly active antiretroviral therapy

As captured in various reviews and commentaries [2,5–7,9–11,35–42], major accomplishments in immunogenetics of HIV-1 infection have largely concentrated on the human leukocyte antigen (HLA) complex (genes for class I, class II, and accessory molecules) and the chemokine receptor (CR) and chemokine ligand (CL) systems participating in both innate and adaptive immunity (Fig. 1) [43,44]. Two other systems are also gaining prominence: those involved in natural killer cell activating and inhibiting receptor/ligand function and in the cytokine networks [45–48]. The molecular and cellular interactions during HIV-1 infection universally relate to products of these established as well as other candidate systems. More recent studies have extended these themes [18,43,49–60] and corroborated the multigenic modulation of HIV-1 infection and pathogenesis [7,61,62].

Fig. 1.:
Consensus findings derived from immunogenetic and pharmacogenetic studies of HIV/AIDS. Host genetic effects can be detected throughout the course of natural (a) and treated (b) HIV-1 infection but are often confounded by other factors (c). Markers consistently showing favorable (F) or unfavorable (U) associations concentrate at HLA class I loci on chromosome 6 and CCR2-CCR5 on chromosome 3. Further evidence suggests that subsets of HLA-B*35 and specific genotypic combinations involving CCR2-CCR5 HHG*2 (both underlined) can account for much if not all of the known effects [43,44]. Several markers with equivocal (?) associations may be more important in certain ethnic groups than in others because of their different frequencies or the contribution from other genes to their distinctive local and extended haplotypes. HLA, Human leukocyte antigen; RANTES, regulated upon activation, normal T cell expressed/secreted; HH, human haplogroup.

HLA and related genes

Although numerous relationships have been reported in single studies of HIV/AIDS [1,2,42], the effects observed most consistently at the population level can be attributed to relatively few HLA class I markers (Fig. 1). HLA-B22 (serological specificity involving HLA–B*55 and −B*56 in Caucasians) [63,64], HLA-B*27, B*35 (or a subset of this group), B*53, B*57, and class I homozygosity [63–68] seem to modify the course of disease progression. Class I allele sharing between an infected donor and a susceptible recipient can accelerate HIV-1 transmission [64,69,70] and viral immune escape [71]. HIV-1 subtype B-infected European Caucasians initially showed associations of the relatively common HLA-B*08 or its haplotype A*01-B*08 (A1–B8 by serology) with rapid CD4 T-cell loss and disease progression [1,2], but those relationships have not been reproduced in later, larger studies [63,65].

Recent work has explored the hypothesis that clusters of HLA class I molecules with peptide-binding pocket homology should confer a similar functional advantage or disadvantage in controlling HIV-1 infection. For example, HLA allelic products corresponding to B*08, B*35, B*53, B*55, and B*56 associated with unfavorable outcomes can all be grouped into the B7 supertype based on their shared peptide binding motifs [72,73]. However, other HLA-B alleles (e.g. B*07) within the B7 supertype have not shown clear relationships. A further suggestion that HLA alleles classified into nine HLA-A and -B supertypes may account more fully for the effects attributed to individual component alleles, including HLA-B*57 and B*58 in the B58 supertype [74,75], will require evaluation in other populations. By contrast, new data on high-risk seronegative Caucasian men who have sex with men and seroconverters [59,76] support another proposition [44] that a subset of B*35 alleles with more specific antigen-presenting characteristics (i.e. preferred binding of epitopes with a non-tyrosine residue at the P9 anchoring position) are more unfavorable for both disease progression and an excess risk of infection. Additional studies have not supported the corollary that B*53 and other alleles closely related to B*35 can operate in the same way [18,70,77].

Apart from a few B*35 alleles [59], no other class I markers with clear pathogenetic effects in infected and untreated individuals have shown comparable effects in those amply exposed but uninfected. The most striking example of disparity in effects between infection and disease is B*57. Recent work has highlighted its dominant control of viremia exerted through cytotoxic T-lymphocyte (CTL) responses mediated by this allele early in the disease process [78,79], while also confirming its ineffectiveness at preventing infection [18,54].

Appreciation that the HLA class I system critically modulates the effectiveness of the CTL response both to natural virus, as summarized above, and to candidate constructs for T-cell-mediated vaccines [80] has been enhanced by other molecular and immunological investigations with broad public health implications. In populations of diverse ethnic ancestry, efforts to map conserved and evolving HIV-1 epitopes commonly recognized by prevalent HLA class I alleles have revealed that certain subregions of HIV-1 proteins are particularly promising targets for incorporation in a vaccine [81,82] because of rare escape mutation and promiscuous binding to multiple class I alleles [83,84]. One new by-product of the exhaustive work on epitope mapping is a model documenting viral evolution under HLA-mediated pressure [85]: evidence that regions of HIV-1 sequences in viral isolates from an individual more readily mutate at the epitope sites specifically targeted by class I alleles to which the virus has been exposed [85,86].

HLA-B and -C molecules not only mediate antigen-presenting function but also interact with the highly variable inhibiting and activating products of genes in the killer immunoglobulin-like receptor (KIR) system. In particular, a Bw4 motif (aa79–84 in the α3 domain) commonly displayed by certain HLA-B alleles is known to stimulate natural killer function. The carriage of alleles with the Bw4 motif appeared to account partly for a favorable course of infection [48]. A biologically persuasive explanation for such an advantage has been the interaction between certain Bw4 motif-bearing alleles and one activating natural killer receptor encoded by the KIR3DS1 gene [51]. The near absence of that KIR locus in African populations probably accounts for their failure to show similar Bw4 protection [87]. Studies of new populations will undoubtedly help define the relative importance of KIR and other genes that govern natural killer activity.

Chemokine receptor and ligand genes

A convincing indication of involvement of chemokine receptors in HIV-1 infection was the discovery that homozygosity for CCR5-Δ32, a null allele resulting from a 32 base pair deletion in the open reading frame of CCR5, conferred nearly complete resistance to infection in heavily exposed seronegative Caucasians [88–91]. Additional polymorphisms in CCR2 and the promoter region of CCR5 also appear to modulate HIV-1 RNA levels early in infection as well as the ultimate course of disease [43,92–95]. A new analysis of time-specific associations of both CCR5-Δ32 and CCR2-64I in cohorts with well-documented effects has suggested that the former protects more uniformly throughout the course of infection, whereas the latter may exert much of its protective effect during early infection [96].

For both the acquisition and progression of infection, comprehensive work on haplotypic relationships of polymorphisms in the CCR2-CCR5 region suggests that HHG*2 (the haplotype carrying CCR5-Δ32) and HHF*2 (the haplotype carrying the CCR2 allele for 64I) are not the only contributory factors [43,92, 97,98]. The HHE/HHE genotype (Fig. 1) appeared to account for the unfavorable promoter effect described earlier [99], and other genotypes containing HHE (e.g. HHC/HHE, the most frequent in north American Caucasians) may also show outcome or race-specific associations with the rapid progression of infection [43,92].

The correlation of CCR5 promoter variants with receptor expression differences is not understood well enough to explain the epidemiological observations [98]. Some encouragement has come from an in-vitro system in which the ease of the CCR5-dependent infection of Langerhans cells differed in a pattern often consistent with the differential population effects of the CCR5 promoter and coding sequence polymorphism [100]. Further advances in elucidating the functional significance of these genetic variants will inevitably accompany the ongoing development of inhibitors of fusion between HIV-1 and its co-receptors [101].

As for the chemokine ligands, elevated levels of several β chemokines (e.g. regulated upon activation, normal T cell expressed/secreted; RANTES) [102] are also known to protect against infection [103,104]. Genotyping data for CCL5 (RANTES) and CCL3 (macrophage-inflammatory protein 1α) have suggested possible roles for different single nucleotide polymorphisms (SNP), either as simple allelic forms or as specific haplotypes, but these relationships are far less clear than those observed with receptor gene variants [49,105–107].

Cytokine genes

Preliminary analyses of cytokine gene variants, mostly SNP, have revealed modest and mostly unconfirmed relationships with HIV/AIDS. In north American Caucasians and African-Americans, the IL10 promoter −592A (5'A) allele has been associated with adverse outcomes after infection [47]. The IL4 promoter variant −589T, initially found in conjunction with elevated serum IgE levels and increased conversion to syncytium-inducing viral forms in seropositive Japanese individuals [46], was subsequently associated with more favorable responses (lower viral load and slower rate of CD4 T-cell depletion) in HIV-infected European Caucasians [52]. More recent studies in Caucasians have not yet resolved these inconsistencies [58,60].

Pharmacogenetics: advances and limitations

In the earliest studies, the protective effect of CCR5-Δ32 (HHG*2) in the context of potent antiretroviral therapy (ART) implied that CCR5 genotyping has the potential to inform clinical decision-making, particularly for patients with atypical responses to therapeutic agents [108–111]. However, success at teasing apart immunogenetic and treatment effects has not been uniform [55,112], and is unlikely to come easily as the wide spectrum of available therapeutic agents, the timing of intervention, and adherence to effective regimens can diminish the discriminatory power in studies of typical design.

The likelihood of uncovering pharmacogenetic determinants of atypical or adverse effects of ART has been exemplified by the strong and consistent association (odds ratio > 10) of HLA-B*57 and its extended haplotype with potentially life-threatening hypersensitivity to abacavir [13,14]. This striking relationship also reflects the importance of population-specific effects: retrospectively analysed data from treated Australians suggested that excluding B*57-positive HIV patients from treatment with abacavir would have reduced the overall frequency of hypersensitivity by threefold [13], but in north Americans, B*57 (or its haplotype) was a much less specific predictor of the abacavir reaction [14]. Moreover, individuals of African ancestry rarely carry the implicated haplotype [Cw*06-B*5701-TNF (−238A)-DRB1*0701-DQB1*0303] (J. Tang and R.A. Kaslow, unpublished); instead they typically carry the B*5703 allele in haplotypes such as Cw*07-B*5703 and Cw*18-B*5703-DRB1*1303-DQB1*0301 [18,113, 114].

In the MDR1 gene encoding the P-glycoprotein, an ABC transporter commonly associated with multidrug resistance, relationships between isolated SNP variants and drug uptake/metabolism may prove useful in guiding clinical trial design and even individual therapeutic decisions [115]. Attempts have usually been made to correlate MDR1 genotypes defined by a single synonymous SNP (3435C > T) with serum P-glycoprotein protein levels [116–119], the uptake of efavirenz, nelfinavir, and other drugs [12,120–123], and degrees of immune reconstitution after ART [12]. However, in both immunogenetic and pharmacogenetic studies, findings based on a single SNP are often difficult to interpret. For example, genotypes defined by the MDR1 3435C > T SNP are highly differentially distributed among various ethnic groups [124,125], and relationships seen in Caucasians are not immediately applicable to other ethnic groups. In addition, an increasing number of MDR1 SNPs and their haplotypes [126,127] can be involved in regulating the function of MDR1 [119,128–130]. MDR1 expression is also regulated by epigenetic factors (e.g. CpG methylation within MDR1 promoter sequences) [131–135] as well as cytokines [136], whose production is, in turn, governed by their own SNPs and haplotypes [137,138]. Finally, as with the multiplicity of immunogenetic effects, polymorphisms in genes encoding other drug transporters such as cytochrome P450, CYP3A4, CYP3A5, CYP2D6, CYP2C19, and multidrug resistance-related proteins (MRP1 and MRP2) [139,140] will also require formal evaluation, either alone or in combination with MDR1 SNPs and haplotypes [12,122].

Host genetics in the era of highly active antiretroviral therapy: opportunities, challenges, and implications

ART and HAART have been successful in reducing the rates of vertical HIV-1 transmission as well as HIV-1-related morbidity and mortality [141–144]. In particular, the mother–child transmission of HIV-1 can be reduced by more than 50% by zidovudine or nevirapine alone [145,146], whereas complete viral suppression and rapid immune recovery are typically achievable after HAART [147,148]. However, HAART has not been readily accessible in regions with the most severe social and public health problems arising from HIV/AIDS [149–151]. For the foreseeable future, the extension of immunogenetic studies to non-European populations [18,94,152,153], distinct in ancestry or HIV-1 subtype exposure, is unlikely to be complicated by HAART. Studies of patients with drug-resistant HIV-1, atypical responses to HAART, or immune restoration diseases after HAART may prove equally informative [53,154–156].

Genome-wide studies

Expensive and life-long HAART is clearly not the best solution to the global control of HIV/AIDS, so continuing immunological investigation coupled with a genome-wide search for immunogenetic and pharmacogenetic determinants should complement the search for alternative interventions, including vaccination. The number of informative SNPs required for a genome-wide survey ranges from 180 000 to 600 000 [157–159] depending on the ethnic background [160]. Research on that scale has been done for several genetically related diseases [161–167]. New information on patterns of linkage disequilibrium (the non-random co-existence of multiple variants on the same chromosome) in representative populations [168] should further reduce the degree of uncertainty about haplotypic or interactive effects. Meanwhile, the spectrum of HIV-related outcomes implies that productive genome-wide screening may need to target multiple conditions or milestones in the course of HIV infection.

Refinements and confirmation

The appropriate replication and refinement of preliminary immunogenetic and pharmacogenetic markers is essential for several reasons. First, because individual studies are rarely uniform in design, sample size (power), outcome measure, genotyping strategy, and statistical approach, inaccuracies of one sort or another are highly likely. Second, the viruses circulating in infected individuals and populations are evolving sufficiently rapidly [85,169–171] that an analysis of genetic effects could often be obscured by the expanded viral usage of alternative co-receptors [172–175], by immune escape mutants [71,176], and by the spread of drug-resistant strains. Third, univariate analyses of individual genetic variations at any level (allele, haplotype, lineage, supertype, allele and haplotype pairing, or zygosity) can often be enhanced by multivariable models capable of defining the relative strength and independence of associations [18,43,51,177], as exemplified in a recent study that confirmed the strong association of B22 with the rapid onset of AIDS in three cohorts of HIV-1-infected Caucasian men [178]. Fourth, as documented in the analyses of CCR5 [179], RANTES (CCL5) [47], SDF1 [180], IL4 [60], and IL10 [181], the diversity and complexity of haplotypes cannot be fully appreciated without systematic studies in different populations.

Genetic profile

As immunogenetic and pharmacogenetic markers are identified and confirmed, efforts to evaluate their joint impact (independent, additive, synergistic, or antagonistic) are increasingly critical. In an analysis of five HLA class I variants on chromosome 6 and two CCR2-CCR5 variants on chromosome 3, more than 50% of African-Americans had at least one of the seven and 5% carried at least one HLA plus one CCR marker. Corresponding frequencies in Caucasians would be higher as a result of the increased presence of HLA-B*27 [114] and CCR5-Δ32 (HHG*2) [88,182]. Compared with individual markers, genetic scores based on simple algorithms showed a stronger correlation with levels of disease control in HIV-1-infected Africans as well as Caucasians [54,66,183]. Alternative scores based on weighted relative hazards also worked well [184]. A demonstration that a profile of host genetic variation carries substantial prognostic value could bring genotyping data to the clinical realm, but the usefulness of host genetic information in supplementing other clinically confirmed assays (e.g. viral load and CD4 T cell counts) remains to be evaluated.

In conclusion, two decades of research have laid important foundations and provided clear evidence that host genetic variation modulates the acquisition and course of HIV-1 infection as well as variable responses to ART. The functional mechanisms for the epidemiologically established relationships involving a dozen or so genetic markers (Fig. 1) at HLA, chemokine receptor, and other loci are being revealed, albeit slowly [76,81, 84,98,185–188]. Innovative molecular technology is effectively reducing barriers to resolution and efficiency in the laboratory, whereas a growing appreciation of the specificity and complexity of genetic effects at the population level may translate into improved study designs and sophisticated data analysis. In time, concerted interactions between epidemiologists, geneticists, immunologists, virologists, and pharmacologists are bound to generate clinically relevant immunogenetic and pharmacogenetic information on HIV/AIDS.


The authors would like to thank Dr R. Coutinho for the invitation to contribute this review article. They would also like to thank Dr J. del Amo and two anonymous reviewers for constructive suggestions and the critical reading of an earlier draft.

Sponsorship: Support for this review and the authors’ own work has come from several grants, including AI40951, AI41530, AI41951, AI51173, CA097247, DA04347, and HD32842 from the National Institutes of Health.


1. Just JJ. Genetic predisposition to HIV-1 infection and acquired immune deficiency syndrome. A review of the literature examining associations with HLA. (Erratum in Hum Immunol 1996, 45:78). Hum Immunol 1995, 44:156–169.
2. Keet IP, Klein MR, Just JJ, Kaslow RA. The role of host genetics in the natural history of HIV-1 infection: the needles in the haystack.AIDS 1996, 10:S59–S67.
3. Cohen OJ, Kinter A, Fauci AS. Host factors in the pathogenesis of HIV disease.Immunol Rev 1997, 159:31–48.
4. Buchacz KA, Wilkinson DA, Krowka JF, Koup RA, Padian NS. Genetic and immunological host factors associated with susceptibility to HIV-1 infection.AIDS 1998, 12 (Suppl. A): S87–S94.
5. Roger M. Influence of host genes on HIV-1 disease progression.FASEB J 1998, 12:625–632.
6. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease.Annu Rev Immunol 1999, 17:657–700.
7. O'Brien SJ, Nelson GW, Winkler CA, Smith MW. Polygenic and multifactorial disease gene association in man: lessons from AIDS.Annu Rev Genet 2000, 34:563–591.
8. Hogan CM, Hammer SM. Host determinants in HIV infection and disease. Part 2: genetic factors and implications for antiretroviral therapeutics.Ann Intern Med 2001, 134: 978–996.
9. Kaslow RA, Bucy RP. Polymorphism in HLA and other elements of the class I and II response pathways. In: Pantaleo G, Walker BD, editors. Retroviral immunology: immune response and restoration. Totowa, NJ: Humana Press, Inc.; 2001. pp. 297–316.
10. Carrington M, O'Brien SJ. The influence of HLA genotype on AIDS.Annu Rev Med 2003, 54:535–551.
11. Huber C, Pons O, Hendel H, Haumont P, Jacquemin L, Tamim S, et al. Genomic studies in AIDS: problems and answers. Development of a statistical model integrating both longitudinal cohort studies and transversal observations of extreme cases.Biomed Pharmacother 2003, 57:25–33.
12. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chavel J-P, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study.Lancet 2002, 359: 30–36.
13. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.Lancet 2002, 359:727–732.
14. Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir.Lancet 2002, 359: 1121–1122.
15. Darby SC, Ewart DW, Giangrande PL, Spooner RJ, Rizza CR. Importance of age at infection with HIV-1 for survival and development of AIDS in UK haemophilia population. UK Haemophilia Centre Directors’ Organisation.Lancet 1996, 347:1573–1579.
16. Paediatric European Network for Treatment of AIDS (PENTA). HIV-1 viral load and CD4 cell count in untreated children with vertically acquired asymptomatic or mild disease.AIDS 1998, 12:F1–F8.
17. Holland CA, Ellenberg JH, Wilson CM, Douglas SD, Futterman DC, Kingsley LA, et al. Relationship of CD4+ T cell counts and HIV type 1 viral loads in untreated, infected adolescents. Adolescent Medicine HIV/AIDS Research Network.AIDS Res Hum Retroviruses 2000, 16:959–963.
18. Tang J, Tang S, Lobashevsky E, Myracle AD, Fideli U, Aldrovandi G, et al. Favorable and unfavorable HLA class I alleles and haplotypes in Zambians predominantly infected with clade C human immunodeficiency virus type 1.J Virol 2002, 76: 8276–8284.
19. Farzadegan H, Hoover DR, Astemborski J, Lyles CM, Margolick JB, Markham RB, et al. Sex differences in HIV-1 viral load and progression to AIDS.Lancet 1998, 352:1510–1514.
20. Lyles CM, Vlahov D, Farzadegan H, Astemborski J, Margolick JB, Masters BA, et al. Comparison of two measures of human immunodeficiency virus (HIV) type 1 load in HIV risk groups.J Clin Microbiol 1998, 36:3647–3652.
21. Fideli US, Allen S, Musunda R, Trask S, Hahn B, Mulenga J, et al. Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 (HIV-1) in Africa.AIDS Res Hum Retroviruses 2001, 17:901–910.
22. Easterbrook PJ, Farzadegan H, Hoover DR, Palenicek J, Chmiel JS, Kaslow RA, et al. Racial differences in rate of CD4 decline in HIV-1-infected homosexual men.AIDS 1996, 10: 1147–1155.
23. Kirchhoff F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC. Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection.N Engl J Med 1995, 332:228–232.
24. Nakata K, Weiden M, Harkin T, Ho D, Rom WN. Low copy number and limited variability of proviral DNA in alveolar macrophages from HIV-1-infected patients: evidence for genetic differences in HIV-1 between lung and blood macrophage populations.Mol Med 1995, 1:744–757.
25. Carre N, Meyer L, Boufassa F, Deveau C, Persoz A, Rouzioux C, et al. High risk of HIV disease progression after infection through a sexual partner with AIDS.AIDS 1996, 10:77–80.
26. Neilson JR, John GC, Carr JK, Lewis P, Kreiss JK, Jackson S, et al. Subtypes of human immunodeficiency virus type 1 and disease stage among women in Nairobi, Kenya.J Virol 1999, 73: 4393–4403.
27. Gottlieb GS, Sow PS, Hawes SE, Ndoye I, Redman M, Coll-Seck AM, et al. Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa.J Infect Dis 2002, 185:905–914.
28. Kaleebu P, French N, Mahe C, Yirrell D, Watera C, Lyagoba F, et al. Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda.J Infect Dis 2002, 185:1244–1250.
29. Sullivan JS. CC chemokine receptor 5 and renal-transplant survival.Lancet 2001, 358:1269–1270.
30. Fischereder M, Luckow B, Hocher B, Wuthrich RP, Rothenpieler U, Schneeberger H, et al. CC chemokine receptor 5 and renal-transplant survival.Lancet 2001, 357:1758–1761.
31. Abdi R, Tran TB, Sahagun-Ruiz A, Murphy PM, Brenner BM, Milford EL, et al. Chemokine receptor polymorphism and risk of acute rejection in human renal transplantation.J Am Soc Nephrol 2002, 13:754–758.
32. Laurence J. Potential roles for chemokine receptor CCR5 in the pathobiology of hepatitis C infection.Gastroenterology 2002, 122:2069–2072.
33. Woitas RP, Ahlenstiel G, Iwan A, Rockstroh JK, Brackmann HH, Kupfer B, et al. Frequency of the HIV-protective CC chemokine receptor 5-Δ32/Δ32 genotype is increased in hepatitis C.Gastroenterology 2002, 122:1721–1728.
34. Schroppel B, Fischereder M, Ashkar R, Lin M, Kramer BK, Mardera B, et al. The impact of polymorphisms in chemokine and chemokine receptors on outcomes in liver transplantation.Am J Transplant 2002, 2:640–645.
35. Hendel H, Cho YY, Gauthier N, Rappaport J, Schachter F, Zagury JF. Contributions of cohort studies in understanding HIV pathogenesis: introduction of the GRIV cohort and preliminary results.Biomed Pharmacother 1996, 50:480–487.
36. Michael NL, Louie LG, Sheppard HW. CCR5-Δ32 gene deletion in HIV-1 infected patients.Lancet 1997, 350:741–742.
37. O'Brien SJ, Dean M. In search of AIDS-resistance genes.Scientific Am 1997, 277:44–51.
38. Kaslow RA, McNicholl JM. Genetic determinants of HIV-1 infection and its manifestations.Proc Assoc Am Physicians 1999, 111:299–307.
39. Vicenzi E, Ghezzi S, Brambilla A, Sheppard HW, Lazzarin A, Poli G, et al. CCR2-64I polymorphism, syncytium-inducing human immunodeficiency virus strains, and disease progression.J Infect Dis 2000, 182:1579–1580.
40. MacDonald KS, Matukas L, Embree JE, Fowke K, Kimani J, Nagelkerke NJ, et al. Human leucocyte antigen supertypes and immune susceptibility to HIV-1, implications for vaccine design.Immunol Lett 2001, 79:151–157.
41. O'Brien SJ, Gao X, Carrington M. HLA and AIDS: a cautionary tale.Trends Mol Med 2001, 7:379–381.
42. Carrington M, Bontrop RE. Effects of MHC class I on HIV/SIV disease in primates.AIDS 2002, 16 (Suppl. 4):S105–S114.
43. Tang J, Shelton B, Makhatadze NJ, Zhang Y, Schaen M, Louie L, et al. Distribution of chemokine receptorCCR2andCCR5genotypes and their relative contribution to human immunodeficiency virus type 1 (HIV-1) seroconversion, early HIV-1 RNA concentration in plasma, and later disease progression.J Virol 2002, 76:662–672.
44. Gao X, Nelson GW, Karacki P, Martin MP, Phair J, Kaslow R, et al. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS.N Engl J Med 2001, 344:1668–1675.
45. Bream JH, Carrington M, O'Toole S, Dean M, Gerrard B, Shin HD, et al. Polymorphisms of the human IFNG gene noncoding regions.Immunogenetics 2000, 51:50–58.
46. Nakayama EE, Hoshino Y, Xin X, Liu H, Goto M, Watanabe N, et al. Polymorphism in the interleukin-4 promoter affects acquisition of human immunodeficiency virus type 1 syncytium-inducing phenotype.J Virol 2000, 74:5452–5459.
47. Shin HD, Winkler C, Stevens JC, Bream J, Young H, Goedert JJ, et al. Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles ofIL10.Proc Natl Acad Sci U S A 2000, 97:14467–14472.
48. Flores-Villanueva PO, Yunis EJ, Delgado JC, Vittinghoff E, Buchbinder S, Leung JY, et al. Control of HIV-1 viremia and protection from AIDS are associated with HLA-Bw4 homozygosity.Proc Natl Acad Sci U S A 2001, 98:5140–5145.
49. An P, Nelson GW, Wang L, Donfield S, Goedert JJ, Phair J, et al. Modulating influence on HIV/AIDS by interacting RANTES gene variants.Proc Natl Acad Sci U S A 2002, 99: 10002–10007.
50. Gonzalez E, Rovin BH, Sen L, Cooke G, Dhanda R, Mummidi S, et al. HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels.Proc Natl Acad Sci U S A 2002, 99:13795–13800.
51. Martin MP, Gao X, Lee JH, Nelson GW, Detels R, Goedert JJ, et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS.Nat Genet 2002, 31:429–434.
52. Nakayama EE, Meyer L, Iwamoto A, Persoz A, Nagai Y, Rouzioux C, et al. Protective effect of interleukin-4 -589T polymorphism on human immunodeficiency virus type 1 disease progression: relationship with virus load.J Infect Dis 2002, 185:1183–1186.
53. Price P, Morahan G, Huang D, Stone E, Cheong KY, Castley A, et al. Polymorphisms in cytokine genes define subpopulations of HIV-1 patients who experienced immune restoration diseases.AIDS 2002, 16:2043–2047.
54. Tang J, Wilson CM, Meleth S, Myracle A, Lobashevsky E, Mulligan MJ, et al. Host genetic profiles predict virological and immunological control of HIV-1 infection in adolescents.AIDS 2002, 16:2275–2284.
55. Wit FW, van Rij RP, Weverling GJ, Lange JM, Schuitemaker H. CC chemokine receptor 5 Δ32 and CC chemokine receptor 2 64I polymorphisms do not influence the virologic and immunologic response to antiretroviral combination therapy in human immunodeficiency virus type 1-infected patients.J Infect Dis 2002, 186:1726–1732.
56. An P, Vlahov D, Margolick JB, Phair J, O'Brien TR, Lautenberger J, et al. A tumor necrosis factor-α-inducible promoter variant of interferon-γ accelerates CD4+ T cell depletion in human immunodeficiency virus-1-infected individuals.J Infect Dis 2003, 188:228–231.
57. Flores-Villanueva PO, Hendel H, Caillat-Zucman S, Rappaport J, Burgos-Tiburcio A, Bertin-Maghit S, et al. Associations of MHC ancestral haplotypes with resistance/susceptibility to AIDS disease development.J Immunol 2003, 170:1925–1929.
58. Kwa D, Van Rij RP, Boeser-Nunnink B, Vingerhoed J, Schuitemaker H. Association between an interleukin-4 promoter polymorphism and the acquisition of CXCR4 using HIV-1 variants.AIDS 2003, 17:981–985.
59. Liu C, Carrington M, Kaslow RA, Gao X, Rinaldo CR, Jacobson LP, et al. Association of polymorphisms in human leukocyte antigen class I and transporter associated with antigen processing genes with resistance to human immunodeficiency virus type 1 infection.J Infect Dis 2003, 187:1404–1410.
60. Modi WS, O'Brien TR, Vlahov D, Buchbinder S, Gomperts E, Phair J, et al. Haplotype diversity in the interleukin-4 gene is not associated with HIV-1 transmission and AIDS progression.Immunogenetics 2003, 55:157–164.
61. McNicholl JM, Cuenco KT. Host genes and infectious diseases – HIV, other pathogens, and a public health perspective.Am J Prevent Med 1999, 16:141–154.
62. Kaslow RA, Tang J, Dorak MT. Chapter 12: The role of host genetic variation in HIV infection and its manifestations. In: AIDS and other manifestations of HIV infection, 4th ed. Wormser GP, editor. New York: Elsevier Science; 2003. in press.
63. Hendel H, Caillat-Zucman S, Lebuanec H, Carrington M, O'Brien S, Andrieu JM, et al. New class I and II HLA alleles strongly associated with opposite patterns of progression to AIDS.J Immunol 1999, 162:6942–6946.
64. Dorak MT, Tang J, Tang S, Coutinho R, Goedert J, Detels R, et al. Association of HLA-B22 with increased plasma HIV-1 RNA concentration and accelerated disease progression to AIDS in Caucasian cohorts. In: 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, 24–28 February 2002 [Abstract 319-w].
65. Carrington M, Nelson GW, Martin MP, Kissner T, Vlahov D, Goedert JJ, et al. HLA and HIV-1: Heterozygosity advantage and B*35-Cw*04 disadvantage.Science 1999, 283: 1748–1752.
66. Keet IP, Tang J, Klein MR, LeBlanc S, Enger C, Rivers C, et al. Consistent associations of HLA class I and class II and transporter gene products with progression of human immunodeficiency virus-1 infection in homosexual men.J Infect Dis 1999, 180:299–309.
67. Tang J, Costello C, Keet IPM, Rivers C, LeBlanc S, Karita E, et al. HLA class I homozygosity accelerates disease progression in human immunodeficiency virus type 1 infection.AIDS Res Hum Retroviruses 1999, 15:317–324.
68. Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, Martino L, et al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors.Proc Natl Acad Sci U S A 2000, 97:2709–2714.
69. MacDonald KS, Embree J, Njenga S, Nagelkerke NJD, Ngatia I, Mohammed Z, et al. Mother–child class I HLA concordance increases perinatal human immunodeficiency virus type 1 infection.J Infect Dis 1998, 177:551–556.
70. MacDonald KS, Fowke KR, Kimani J, Dunand VA, Nagelkerke NJD, Ball TB, et al. Influence of HLA supertypes on susceptibility and resistance to human immunodeficiency virus type 1 infection.J Infect Dis 2000, 181:1581–1589.
71. Goulder PJ, Brander C, Tang Y, Tremblay C, Colbert RA, Addo MM, et al. Evolution and transmission of stable CTL escape mutations in HIV infection.Nature 2001, 412:334–338.
72. Sette A, Sidney J. HLA supertypes and supermotifs: a functional perspective on HLA polymorphism.Curr Opin Immunol 1998, 10:478–482.
73. Sette A, Sidney J. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism.Immunogenetics 1999, 50:201–212.
74. Trachtenberg E, Korber B, Sollars C, Hayes E, Funkhouser R, Kepler T, et al. Association of HLA class I supertypes with HIV-1 disease progression in the Chicago MACS: evidence for frequency-dependent selection.Hum Immunol 2002, 63 (Suppl. 1):S32.
75. Trachtenberg E, Korber B, Sollars C, Kepler TB, Hraber PT, Hayes E, et al. Advantage of rare HLA supertype in HIV disease progression.Nat Med 2003, 9:928–935.
76. Jin X, Gao X, Ramanathan M Jr, Deschenes GR, Nelson GW, O'Brien SJ, et al. Human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T-cell responses for groups of HIV-1-infected individuals with different HLA-B*35 genotypes.J Virol 2002, 76:12603–12610.
77. MacDonald KS, Embree JE, Nagelkerke NJ, Castillo J, Ramhadin S, Njenga S, et al. The HLA A2/6802 supertype is associated with reduced risk of perinatal human immunodeficiency virus type 1 transmission.J Infect Dis 2001, 183:503–506.
78. Migueles SA, Laborico AC, Imamichi H, Shupert WL, Royce C, McLaughlin M, et al. The differential ability of HLA B*5701+ long-term nonprogressors and progressors to restrict human immunodeficiency virus replication is not caused by loss of recognition of autologous viralgagsequences.J Virol 2003, 77:6889–6898.
79. Altfeld M, Addo MM, Rosenberg ES, Hecht FM, Lee PK, Vogel M, et al. Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. In: 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA, 10–14 February 2003 [Abstract #510].
80. Kaslow RA, Rivers CR, Tang J, Bender TJ, Goepfert PA, El Habib R, et al. Polymorphisms in HLA class I genes associated with both favorable prognosis of human immunodeficiency virus (HIV) type 1 infection and positive cytotoxic T-lymphocyte responses to ALVAC-HIV recombinant canarypox vaccines.J Virol 2001, 75:8681–8689.
81. Gillespie GM, Kaul R, Dong T, Yang HB, Rostron T, Bwayo JJ, et al. Cross-reactive cytotoxic T lymphocytes against a HIV-1 p24 epitope in slow progressors with B*57.AIDS 2002, 16: 961–972.
82. Bansal A, Sabbaj S, Edwards BH, Ritter D, Perkins C, Tang J, et al. T-cell responses to Gag, Pol, Env and Nef in HIV-1-infected African-American and Hispanic adolescents.AIDS Res Hum Retroviruses 2003; 19:1017–1026.
83. Addo MM, Yu XG, Rathod A, Cohen D, Eldridge RL, Strick D, et al. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load.J Virol 2003, 77:2081–2092.
84. Sabbaj S, Bansal A, Ritter GD, Perkins C, Edwards BH, Gough E, et al. Cross-reactive CD8+ T cell epitopes identified in US adolescent minorities.J Acquired Immune Defic Syndr 2003, 33:426–438.
85. Moore CB, John M, James IR, Christiansen FT, Witt CS, Mallal SA. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level.Science 2002, 296:1439–1443.
86. McMichael A, Klenerman P. HIV/AIDS. HLA leaves its footprints on HIV.Science 2002, 296:1410–1411.
87. Kaslow RA, Tang J, Dorak MT, Tang S, Musonda R, Karita E, et al. Homozygosity for HLA-Bw4 is not associated with protection of HIV-1-infected persons of African ancestry. In: 9th Conferences on Retroviruses and Opportunistic Infections. Seattle, WA, 24–28 February 2002 [Abstract #320-w].
88. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a common deletion allele of the chemokine receptor 5 structural gene.Science 1996, 273: 1856–1862.
89. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection.Cell 1996, 86:367–377.
90. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene.Nature 1996, 382:722–725.
91. Zimmerman PA, Buckler-White A, Alkhatib G, Spalding T, Kubofcik J, Combadiere C, et al. Inherited resistance of HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk.Mol Med 1997, 3:23–36.
92. Gonzalez E, Bamshad M, Sato N, Mummidi S, Dhanda G, Catano G, et al. Race-specific HIV-1 disease modifying effects associated withCCR5haplotypes.Proc Natl Acad Sci U S A 1999, 96:12004–12009.
93. Ioannidis JP, Rosenberg PS, Goedert JJ, Ashton LJ, Benfield TL, Buchbinder SP, et al. Effects of CCR5-Δ32, CCR2-64I and SDF-1 3'A alleles on HIV disease progression: an international meta-analysis of individual-patient data.Ann Intern Med 2001, 135:782–795.
94. Mangano A, Gonzalez E, Dhanda R, Catano G, Bamshad M, Bock A, et al. Concordance between the CC chemokine receptor 5 genetic determinants that alter risks of transmission and disease progression in children exposed perinatally to human immunodeficiency virus.J Infect Dis 2001, 183: 1574–1585.
95. Tang J, Wilson CM, Schaen M, Myracle AD, Douglas SD, Kaslow RA. CCR2andCCR5genotypes in HIV type 1-infected adolescents: limited contributions to variability in plasma HIV type 1 RNA concentration in the absence of antiretroviral therapy.AIDS Res Hum Retroviruses 2002, 18:403–412.
96. Mulherin SA, O'Brien TR, Ioannidis JP, Goedert JJ, Buchbinder SP, Coutinho RA, et al. Effects of CCR5-Δ32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection.AIDS 2003, 17:377–387.
97. Mummidi S, Ahuja SS, Gonzalez E, Anderson SA, Santiago EN, Stephan KT, et al. Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression.Nat Med 1998, 4:786–793.
98. Mummidi S, Bamshad M, Ahuja SS, Gonzalez E, Feuillet PM, Begum K, et al. Evolution of human and non-human primate CC chemokine receptor 5 gene and mRNA. Potential roles for haplotype and mRNA diversity, differential haplotype-specific transcriptional activity, and altered transcription factor binding to polymorphic nucleotides in the pathogenesis of HIV-1 and simian immunodeficiency virus.J Biol Chem 2000, 275: 18946–18961.
99. Martin MP, Dean M, Smith MW, Winkler C, Gerrard B, Michael NL, et al. Genetic acceleration of AIDS progression by a promoter variant ofCCR5.Science 1998, 282:1907–1911.
100. Kawamura T, Gulden FO, Sugaya M, McNamara DT, Borris DL, Lederman MM, et al. R5 HIV productively infects Langerhans cells, and infection levels are regulated by compoundCCR5polymorphisms.Proc Natl Acad Sci U S A 2003, 100: 8401–8406.
101. Trkola A, Kuhmann SE, Strizki JM, Maxwell E, Ketas T, Morgan T, et al. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use.Proc Natl Acad Sci U S A 2002, 99:395–400.
102. Zagury D, Lachgar A, Chams V, Fall LS, Bernard J, Zagury JF, et al. C-C chemokines, pivotal in protection against HIV type 1 infection.Proc Natl Acad Sci U S A 1998, 95:3857–3861.
103. Oliva A, Kinter AL, Vaccarezza M, Rubbert A, Catanzaro A, Moir S, et al. Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replicationin vitro.J Clin Invest 1998, 102:223–231.
104. Paxton WA, Liu R, Kang S, Wu L, Gingeras TR, Landau NR, et al. Reduced HIV-1 infectability of CD4+ lymphocytes from exposed-uninfected individuals: association with low expression of CCR5 and high production of beta-chemokines.Virology 1998, 244:66–73.
105. Liu HL, Chao D, Nakayama EE, Taguchi H, Goto M, Xin XM, et al. Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression.Proc Natl Acad Sci U S A 1999, 96:4581–4585.
106. McDermott DH, Beecroft MJ, Kleeberger CA, Al-Sharif FM, Ollier WE, Zimmerman PA, et al. Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the Multicenter AIDS Cohort Study.AIDS 2000, 14:2671–2678.
107. Gonzalez E, Dhanda R, Bamshad M, Mummidi S, Geevarghese R, Catano G, et al. Global survey of genetic variation in CCR5, RANTES, and MIP-1α: Impact on the epidemiology of the HIV-1 pandemic.Proc Natl Acad Sci U S A 2001, 98:5199–5204.
108. Valdez H, Purvis SF, Lederman MM, Fillingame M, Zimmerman PA. Association of the CCR5Δ32 mutation with improved response to antiretroviral therapy.JAMA 1999, 282:734.
109. O'Brien TR, McDermott DH, Ioannidis JP, Carrington M, Murphy PM, Havlir DV, et al. Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy.AIDS 2000, 14:821–826.
110. Guerin S, Meyer L, Theodorou I, Boufassa F, Magierowska M, Goujard C, et al. CCR5 Δ32 deletion and response to highly active antiretroviral therapy in HIV-1-infected patients.AIDS 2000, 14:2788–2790.
111. Barroga CF, Raskino C, Fangon MC, Palumbo PE, Baker CJ, Englund JA, et al. The CCR5 Δ32 allele slows disease progression of human immunodeficiency virus-1-infected children receiving antiretroviral treatment.J Infect Dis 2000, 182: 413–419.
112. Yamashita TE, Phair JP, Munoz A, Margolick JB, Detels R, O'Brien SJ, et al. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study.AIDS 2001, 15:735–746.
113. Tang J, Naik E, Costello C, Karita E, Rivers C, Allen S, et al. Characteristics of HLA class I and class II polymorphisms in Rwandan women.Exp Clin Immunogenet 2000, 17:185–198.
114. Cao K, Hollenbach J, Shi X, Shi W, Chopek M, Fernandez-Vina MA. Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations.Hum Immunol 2001, 62:1009–1030.
115. Brinkmann U, Roots I, Eichelbaum M. Pharmacogenetics of the human drug-transporter gene MDR1: impact of polymorphisms on pharmacotherapy.Drug Discov Today 2001, 6:835–839.
116. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P- glycoprotein expression and activityin vivo.Proc Natl Acad Sci U S A 2000, 97:3473–3478.
117. Dresser MJ. TheMDR1C3435T polymorphism: effects on P-glycoprotein expression/function and clinical significance.AAPS PharmSci 2001, 3:3.
118. Kerb R, Hoffmeyer S, Brinkmann U. ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2.Pharmacogenomics 2001, 2:51–64.
119. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans.Clin Pharmacol Ther 2001, 70:189–199.
120. Hitzl M, Drescher S, van der Kuip H, Schaffeler E, Fischer J, Schwab M, et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells.Pharmacogenetics 2001, 11:293–298.
121. Sakaeda T, Nakamura T, Horinouchi M, Kakumoto M, Ohmoto N, Sakai T, et al. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects.Pharm Res 2001, 18:1400–1404.
122. Kerb R, Aynacioglu AS, Brockmoller J, Schlagenhaufer R, Bauer S, Szekeres T, et al. The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels.Pharmacogenomics J 2001, 1:204–210.
123. Drescher S, Schaeffeler E, Hitzl M, Hofmann U, Schwab M, Brinkmann U, et al. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine.Br J Clin Pharmacol 2002, 53:526–534.
124. Ameyaw MM, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity.Pharmacogenetics 2001, 11:217–221.
125. Schaeffeler E, Eichelbaum M, Brinkmann U, Penger A, Asante-Poku S, Zanger UM, et al. Frequency of C3435T polymorphism of MDR1 gene in African people.Lancet 2001, 358:383–384.
126. Kim RB. MDR1 single nucleotide polymorphisms: multiplicity of haplotypes and functional consequences.Pharmacogenetics 2002, 12:425–427.
127. Tang K, Ngoi SM, Gwee PC, Chua JM, Lee EJ, Chong SS, et al. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations.Pharmacogenetics 2002, 12:437–450.
128. Horinouchi M, Sakaeda T, Nakamura T, Morita Y, Tamura T, Aoyama N, et al. Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: functional relevance to pharmacokinetics of digoxin.Pharm Res 2002, 19: 1581–1585.
129. Johne A, Kopke K, Gerloff T, Mai I, Rietbrock S, Meisel C, et al. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene.Clin Pharmacol Ther 2002, 72:584–594.
130. Potocnik U, Ravnik-Glavac M, Glavac D. Functional MDR1 polymorphisms (G2677T and C3435T) and TCF4 mutations in colorectal tumors with high microsatellite instability.Cell Mol Biol Lett 2002, 7:92–95.
131. Desiderato L, Davey MW, Piper AA. Demethylation of the humanMDR15’ region accompanies activation of P-glycoprotein expression in a HL60 multidrug resistant subline.Somat Cell Mol Genet 1997, 23:391–400.
132. Kantharidis P, El-Osta A, deSilva M, Wall DM, Hu XF, Slater A, et al. Altered methylation of the humanMDR1promoter is associated with acquired multidrug resistance.Clin Cancer Res 1997, 3:2025–2032.
133. Nakayama M, Wada M, Harada T, Nagayama J, Kusaba H, Ohshima K, et al. Hypomethylation status of CpG sites at the promoter region and overexpression of the humanMDR1gene in acute myeloid leukemias.Blood 1998, 92:4296–4307.
134. Fryxell KB, McGee SB, Simoneaux DK, Willman CL, Cornwell MM. Methylation analysis of the human multidrug resistance 1 gene in normal and leukemic hematopoietic cells.Leukemia 1999, 13:910–917.
135. Kusaba H, Nakayama M, Harada T, Nomoto M, Kohno K, Kuwano M, et al. Association of 5’ CpG demethylation and altered chromatin structure in the promoter region with transcriptional activation of the multidrug resistance 1 gene in human cancer cells.Eur J Biochem 1999, 262:924–932.
136. Bertilsson PM, Olsson P, Magnusson KE. Cytokines influence mRNA expression of cytochrome P450 3A4 and MDRI in intestinal cells.J Pharm Sci 2001, 90:638–646.
137. Bidwell J, Keen L, Gallagher G, Kimberly R, Huizinga T, McDermott MF, et al. Cytokine gene polymorphism in human disease: on-line databases.Genes Immunol 1999, 1:3–19.
138. Haukim N, Bidwell JL, Smith AJ, Keen LJ, Gallagher G, Kimberly R, et al. Cytokine gene polymorphism in human disease: on-line databases.Genes Immunol 2002, 3 (Suppl. 2):313–330.
139. Liu Y, Hu M. P-glycoprotein and bioavailability-implication of polymorphism.Clin Chem Lab Med 2000, 38:877–881.
140. Ito S, Ieiri I, Tanabe M, Suzuki A, Higuchi S, Otsubo K. Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects.Pharmacogenetics 2001, 11:175–184.
141. Gebhardt M, Rickenbach M, Egger M. Impact of antiretroviral combination therapies on AIDS surveillance reports in Switzerland. Swiss HIV Cohort Study.AIDS 1998, 12:1195–1201.
142. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.N Engl J Med 1998, 338:853–860.
143. Mocroft A, Sabin CA, Youle M, Madge S, Tyrer M, Devereux H, et al. Changes in AIDS-defining illnesses in a London Clinic, 1987–1998.J Acquired Immune Defic Syndr 1999, 21: 401–407.
144. Richman DD. HIV chemotherapy.Nature 2001, 410: 995–1001.
145. Van Dyke RB, Korber BT, Popek E, Macken C, Widmayer SM, Bardeguez A, et al. The Ariel Project: A prospective cohort study of maternal–child transmission of human immunodeficiency virus type 1 in the era of maternal antiretroviral therapy. [Published erratum appears in J Infect Dis 1999, 179:754]. J Infect Dis 1999, 179:319–328.
146. Moodley D, Moodley J, Coovadia H, Gray G, McIntyre J, Hofmyer J, et al. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1.J Infect Dis 2003, 187:725–735.
147. Kaufmann GR, Zaunders JJ, Cunningham P, Kelleher AD, Grey P, Smith D, et al. Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection.AIDS 2000, 14:2643–2651.
148. Plana M, Martinez C, Garcia F, Maleno MJ, Barcelo JJ, Garcia A, et al. Immunologic reconstitution after 1 year of highly active antiretroviral therapy, with or without protease inhibitors.J Acquired Immune Defic Syndr 2002, 29:429–434.
149. Centers for Disease Control and Prevention. The global HIV and AIDS epidemic, 2001.MMWR 2001, 50:434–439.
150. Piot P, Bartos M, Ghys PD, Walker N, Schwartlander B. The global impact of HIV/AIDS.Nature 2001, 410:968–973.
151. Schwartlander B, Stover J, Walker N, Bollinger L, Gutierrez JP, McGreevey W, et al. AIDS. Resource needs for HIV/AIDS.Science 2001, 292:2434–2436.
152. Costello C, Tang J, Rivers C, Karita E, Meizen-Derr J, Allen S, et al. HLA-B*5703 independently associated with slower HIV-1 disease progression in Rwandan women.AIDS 1999, 13: 1990–1991.
153. Dorak MT, Tang J, Westfall A, Zulu I, Leakeas CL, Schaen MM, et al. HLA class I effects on transmission of HIV-1C in heterosexual Zambian couples: risk of concordance at HLA-B. In: XIVth International AIDS Conference. Barcelona, Spain, 7–12 July 2002 [Abstract WePeA5765] (Book II, p. 18).
154. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions.Ann Intern Med 1999, 131:81–87.
155. Wit FW, van Leeuwen R, Weverling GJ, Jurriaans S, Nauta K, Steingrover R, et al. Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons.J Infect Dis 1999, 179:790–798.
156. Price DA, Scullard G, Oxenius A, Braganza R, Beddows SA, Kazmi S, et al. Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity.J Virol 2003, 77:6041–6049.
157. Daly MJ, Rioux JD, Schaffner SF, Hudson TJ, Lander ES. High-resolution haplotype structure in the human genome.Nat Genet 2001, 29:229–232.
158. Patil N, Berno AJ, Hinds DA, Barrett WA, Doshi JM, Hacker CR, et al. Blocks of limited haplotype diversity revealed by high-resolution scanning of human chromosome 21.Science 2001, 294:1719–1723.
159. Stephens JC, Schneider JA, Tanguay DA, Choi J, Acharya T, Stanley SE, et al. Haplotype variation and linkage disequilibrium in 313 human genes.Science 2001, 293:489–493.
160. Judson R, Salisbury B, Schneider J, Windemuth A, Stephens JC. How many SNPs does a genome-wide haplotype map require?Pharmacogenomics 2002, 3:379–391.
161. Todd JA. Genetic analysis of type 1 diabetes using whole genome approaches.Proc Natl Acad Sci U S A 1995, 92: 8560–8565.
162. Satsangi J, Parkes M, Louis E, Hashimoto L, Kato N, Welsh K, et al. Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12.Nat Genet 1996, 14:199–202.
163. Nichols WC, Koller DL, Slovis B, Foroud T, Terry VH, Arnold ND, et al. Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-32.Nat Genet 1997, 15:277–280.
164. Concannon P, Gogolin-Ewens KJ, Hinds DA, Wapelhorst B, Morrison VA, Stirling B, et al. A second-generation screen of the human genome for susceptibility to insulin-dependent diabetes mellitus.Nat Genet 1998, 19:292–296.
165. Xu J, Wiesch DG, Meyers DA. Genetics of complex human diseases: genome screening, association studies and fine mapping.Clin Exp Allergy 1998, 28 (Suppl. 5):1–5; discussion 26–28.
166. Schuckit MA. Genetics of the risk for alcoholism.Am J Addict 2000, 9:103–112.
167. Terwilliger JD. On the resolution and feasibility of genome scanning approaches.Adv Genet 2001, 42:351–391.
168. Ardlie KG, Kruglyak L, Seielstad M. Patterns of linkage disequilibrium in the human genome.Nat Rev Genet 2002, 3:299–309.
169. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, et al. Viral dynamics in human immunodeficiency virus type 1 infection.Nature 1995, 373:117–122.
170. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.Nature 1995; 373:123–126.
171. Borrow P, Lweicki H, Wei X, Horwitz M, Peffer N, Meyers H, et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus.Nat Med 1997, 3: 205–211.
172. Balotta C, Bagnarelli P, Violin M, Ridolfo AL, Zhou D, Berlusconi A, et al. Homozygous Δ32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient.AIDS 1997, 11: F67–F71.
173. Biti R, Ffrench R, Young J, Bennetts B, Stewart G. HIV-1 infection in an individual homozygous for theCCR5deletion allele.Nat Med 1997, 3:252–253.
174. D'Aquila RT, Sutton L, Savara A, Hughes MD, Johnson VA, NIAID AIDS Clinical Trials Group Protocol 241 Virology Team. CCR5/Δ(ccr5) heterozygosity: a selective pressure for the syncytium-inducing human immunodeficiency virus type 1 phenotype.J Infect Dis 1998, 177:1549–1553.
175. Michael NL, Nelson JAE, Kewalramani VN, Chang G, O'Brien SJ, Mascola JR, et al. Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5-Δ32.J Virol 1998, 72:6040–6047.
176. Goulder PJ, Phillips RE, Cobert RA, McAdam S, Ogg G, Nowak MA, et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS.Nat Med 1997, 3:212–217.
177. Magierowska M, Theodorou I, Debre P, Sanson F, Autran B, Riviere Y, et al. Combined genotypes of CCR5, CCR2, SDF1, and HLA genes can predict the long-term nonprogressor status in human immunodeficiency virus-1-infected individuals.Blood 1999, 93:936–941.
178. Dorak MT, Tang J, Tang S, Penman-Aguilar A, Coutinho R, Goedert J, et al.Influence of human leukocyte antigen-B22 alleles on the course of human immunodeficiency virus type 1 infection in 3 cohorts of white men.J Infect Dis 2003, 188:856–862.
179. Bamshad MJ, Mummidi S, Gonzalez E, Ahuja SS, Dunn DM, Watkins WS, et al. A strong signature of balancing selection in the 5’ cis-regulatory region of CCR5.Proc Natl Acad Sci U S A 2002, 99:10539–10544.
180. Johnson GC, Esposito L, Barratt BJ, Smith AN, Heward J, Di Genova G, et al. Haplotype tagging for the identification of common disease genes.Nat Genet 2001, 29:233–237.
181. Gibson AW, Edberg JC, Wu J, Westendorp RG, Huizinga TW, Kimberly RP. Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production and enhance the risk of systemic lupus erythematosus.J Immunol 2001, 166: 3915–3922.
182. Martinson JJ, Chapman NH, Rees DC, Liu YT, Clegg JB. Global distribution of the CCR5 gene 32-basepair deletion.Nat Genet 1997, 16:100–103.
183. Kaslow RA, Carrington M, Apple R, Park L, Munoz A, Saah AJ, et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection.Nat Med 1996, 2:405–411.
184. Carrington M, Nelson G, O'Brien SJ. Considering genetic profiles in functional studies of immune responsiveness to HIV-1.Immunol Lett 2001, 79:131–140.
185. Goulder PJR, Bunce M, Krausa P, McIntyre K, Crowley S, Morgan B, et al. Novel, cross-restricted, conserved and immunodominant epitopes I. slow progressors in HIV infection.AIDS Res Hum Retroviruses 1996, 12:1691–1698.
186. Balla-Jhagjhoorsingh SS, Koopman G, Mooij P, Haaksman TGM, Teeuwsen VJP, Bontrop RE, et al. Conserved CTL epitope shared between HIV-infected human long-term survivors and chimpanzees.J Immunol 1999, 162:2308–2314.
187. Kaul R, Dong T, Plummer FA, Kimani J, Rostron T, Kiama P, et al. CD8(+) lymphocytes respond to different HIV epitopes in seronegative and infected subjects.J Clin Invest 2001, 107:1303–1310.
188. Sriwanthana B, Hodge T, Mastro TD, Dezzutti CS, Bond K, Stephens HA, et al. HIV-specific cytotoxic T lymphocytes, HLA-A11, and chemokine-related factors may act synergistically to determine HIV resistance in CCR5 Δ32-negative female sex workers in Chiang Rai, northern Thailand.AIDS Res Hum Retroviruses 2001, 17:719–734.

AIDS; HIV; immunogenetics; pharmacogenetics; therapy

© 2003 Lippincott Williams & Wilkins, Inc.